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Abstract
Despite more than 75 years of research by some of the greatest scientists in the world to conquer cancer, the clear winner is still cancer.
This is reflected particularly by liver cancer that worldwide ranks fourth in terms of mortality with survival rates of no more than 3–5%.
Significantly, one of the earliest discovered hallmarks of cancer had its roots in Bioenergetics as many tumors were found in the 1920s to
exhibit a high glycolytic phenotype. Although research directed at unraveling the underlying basis and significance of this phenotype
comprised the focus of cancer research for almost 50 years, these efforts declined greatly from 1970 to 1990 as research into the molecular
and cell biology of this disease gained center stage. Certainly, this change was necessary as the new knowledge obtained about oncogenes,
gene regulation, and programmed cell death once again placed Bioenergetics in the limelight of cancer research. Thus, we now have a much
better molecular understanding of the high glycolytic phenotype of many cancers, the pivotal roles that Type II hexokinase-mitochondrial
interactions play in this process to promote tumor cell growth and survival, and how this new knowledge can lead to improved therapies that
may ultimately turn the tide on our losing war on cancer.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Background: the high glycolytic cancer phenotype and
its link to mitochondrial bound hexokinase
One of the most common, profound, intriguing, and
insidious phenotypes of highly malignant tumors, known
for more than seven decades, is their ability to metabolize
glucose at high rates [1–6]. This is a characteristic of highly
malignant animal and human tumors including those
derived from brain, breast, colon, liver, lung, pancreas,
stomach, and retina [1,2]. For each, a close correlation
exists among the degree of differentiation, growth rate,
and glucose metabolism, where the most poorly differ-
entiated tumors exhibit the fastest growth and the highest
glycolytic rate [3–5]. In fact, this unique phenotype is used
clinically worldwide via positron emission tomography
(PET) to detect the most malignant tumors, and in some
cases even predict patient survival time [7–9]. Despite the
commonality of the high glycolytic phenotype, and its
widespread use clinically as a diagnostic tool, it has not
been exploited as a major target for arresting or slowing the
growth of cancer cells. However, this neglect may be short
lived as the underlying molecular basis of the high glyco-
lytic phenotype is now known to involve a number of
genetic and biochemical events [6], one of the most impor-
tant of which is the overexpression of a mitochondrial
bound form of hexokinase [10–21], now clearly identified
as Type II [18–21]. It is this hexokinase isoform that
constitutes the basis of this minireview. Significantly, evi-
dence is mounting that Type II hexokinase plays a pivotal
role in highly malignant cancer cells in promoting cell
growth and survival, and for this reason may represent an
ideal target in aggressive tumors for therapeutic interven-
tion.
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2. Properties of Type II hexokinase: Km, molecular
weight, and overexpression in tumors
Hexokinases (ATP: D-hexose-6-phosphotransferases) cat-
alyze the first step in the glycolytic pathway as indicated
below:
Glucoseþ ATPfGlucose-6-Phosphateþ ADP
There are four major isozymes of hexokinase, referred to as
Types I, II, III and IV (glucokinase) (reviewed in Refs. [22–
25]). Types I–III show a high affinity (Km = 0.02–0.03
mM) for glucose, are product inhibited by glucose-6-phos-
phate (G-6-P), and have a molecular mass near 100 kDa. In
contrast, the Type IV isozyme (glucokinase) has a much
lower affinity for glucose (Km= 5–8 mM), is insensitive to
product inhibition by G-6-P, and has a molecular mass near
50 kDa. The cDNA encoding each hexokinase isozyme has
been cloned and sequenced from its major tissues of origin
[21,26–29], and as discussed in greater detail below, the
sequences obtained implicate a ‘‘gene duplication’’ explan-
ation for the 100-kDa Type-I–III hexokinases.
Hexokinase isozymes from tumors exhibiting the high
glycolytic phenotype have been cloned and sequenced also
[21,30]. Significantly, these sequences correspond to Type II
hexokinase, the major isozyme overexpressed ( > 100-fold)
in such tumors, and found normally in muscle and adipose
tissue in low amounts. Type I hexokinase, found normally in
brain, breast, kidney, and retina is present also in some
highly glycolytic tumors [19,20,31–33], but at very low
levels relative to the Type II isozyme. Possible exceptions
are brain tumors [34,35] where the Type I enzyme may be
higher. Nevertheless, recent work shows that the Type II
enzyme, nearly absent in normal brain tissue, is expressed in
significant amounts in gliomas [36]. The same pattern
applies to many human breast cancers where 45% of all
samples examined in a recent study contained Type II
hexokinase [37]. Finally, although Type I hexokinase is
also the predominant form of hexokinase in normal retina
tissue, retinoblastoma and a retinoblastoma cell line express
considerable amounts of the Type II isozyme [38]. Although
more work needs to be done, there should be some concern
if significant amounts of Type II hexokinase are found in a
biopsy of a tumor derived from a tissue that normally does
not express this isoform. It may mean that the tumor is
already of the rapidly growing, highly glycolytic type or that
it is on its way to becoming such.
3. Mitochondrial binding of Type II hexokinase in
tumors: facilitation of glycolysis and inhibition of cell
death
Type II hexokinase binds to transmembrane channels
formed by the protein called ‘‘porin’’ or ‘‘VDAC’’ [15]
located within the outer mitochondrial membrane. This
interaction (Fig. 1A) markedly reduces the enzyme’s sensi-
tivity to product inhibition by G-6-P [14], provides preferred
access to mitochondrially generated ATP [39], and protects
against proteolytic degradation [40]. As we described earlier
[5,39,41,42], these combined properties, together with the
high content of the enzyme in highly malignant tumors
(>100-fold elevation), result in the rapid production of G-6-
P. This key metabolic intermediate-precursor serves not only
as a major carbon source for most biosynthetic pathways
that are essential for the growth and rapid proliferation of
tumors, but also as the initial substrate for glycolysis that
generates ATP synthesis during its catabolism to lactate
(Fig. 1A) (reviewed in Refs. [43,44]). Under aerobic con-
ditions, as much as half the ATP produced in some tumor
cells may be derived from glycolysis [2,45], in sharp
contrast to normal cells where this value is usually less than
10% and oxidative phosphorylation is the predominant
method for ATP generation. Under hypoxic (low oxygen
tension) conditions near the core of solid tumors, the already
high glycolytic rate may double [4] allowing at least some
cells to not only survive but to undergo further mutations
that increase their malignancy [46] and prepare them for
metastasis [47].
Regarding the above, it is perhaps important to note that
the extent to which a highly malignant tumor cell may
generate its ATP from glycolysis is likely to depend on its
local physiological/metabolic state. For example, if ample
oxygen and mitochondrial substrates are available, it is
likely that more ATP will be generated by mitochondrial
oxidative phosphorylation than by glycolysis. However, if
either of these staples is in short supply, for example, during
hypoxia or during metastatic migration, more ATP will be
generated by glycolysis than by mitochondrial oxidative
phosphorylation, thus assuring tumor cell survival.
Interestingly, recent studies strongly indicate that highly
malignant cancer cells employ Type II hexokinase not only
to assure their survival during abrupt changes in physio-
logical/metabolic state, but also to protect them against cell
death, perhaps while the latter changes are taking place.
Thus, mitochondrial binding of Type II hexokinase to the
outer mitochondrial membrane has been shown to inhibit
Bax-induced cytochrome c release and apoptosis in HeLa
cells [48]. Other recent work suggests that both survival
mechanisms noted above may be related to growth-factor-
induced signaling pathways dependent on the serine/threo-
nine kinase Akt/PKB, a major downstream effector of
growth-factor-mediated cell survival [49–51]. Thus, growth
factors acting through signaling pathways are believed to
facilitate or enhance the binding of Type II hexokinase to
the outer mitochondrial membrane, a view that had been
suggested much earlier [52] but largely ignored. Perhaps
growth-related signaling pathways that might normally
control binding and debinding of Type II hexokinase in
normal cells (e.g., muscle and adipose) have been altered in
poorly differentiated cancer cells, such that this enzyme
remains ‘‘locked’’ to the outer mitochondrial membrane thus
enhancing cell survival, the malignant state, and the poten-
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tial for metastasis. Certainly, a very interesting story is now
beginning to unfold with Type II hexokinase as a central
player in the highly malignant cancer cell’s capacity to
survive a variety of stress situations.
4. Molecular and structural biology of Type II
hexokinase
4.1. Chromosomal location
Interestingly, each of the four hexokinase isoforms is
located on a different chromosome in both rats and human
with Type II hexokinase, the subject of this review, being
located on rat chromosome 4 and human chromosome 2.
More specifically, in the rat, hexokinase Types I, II, III, and
IV (glucokinase) have been assigned to chromosome bands
20q11, 4q34, 17q12, and 14q21, respectively [53]. In
humans, Type II hexokinase has been mapped to the
chromosome 2p13 locus [54], glucokinase to 7p22 [55]
and 7p13 [56], Type I hexokinase to the short (10p11) or
long arm (10q11) of chromosome 10 [57], and Type III
hexokinase to 5q35 [58,59].
4.2. Gene duplication and three-dimensional structure
As indicated above, hexokinases Types I–III share two
common properties; they have molecular weights of approx-
imately 100 kDa and are sensitive to feedback inhibition by
the product G-6-P. In contrast, Type IV hexokinase (gluco-
kinase) has a molecular weight of approximately 50 kDa and
is insensitive to inhibition by physiologically relevant con-
centrations of G-6-P. As such, mammalian glucokinase
resembles hexokinases of yeast [60] that are insensitive to
inhibition by G-6-P, and have molecular weights near 50
kDa. These observations implicate an evolutionary relation-
ship, where the 100-kDa Types I–III mammalian hexoki-
nases evolved from an ancestral 50-kDa enzyme similar to
the yeast enzyme via a gene duplication and fusion event
[61–64]. The ‘‘gene duplication’’ view has gained excellent
support from studies where the cDNA corresponding to each
hexokinase has been cloned and sequenced and the exon–
intron structure mapped, for example, for the Type II
hexokinase [63]. Thus, based on cDNA data, and the
deduced primary sequence [21,26–28], each of the two
50-kDa halves (denoted N and C) of the Types I– III
isozymes show close homology to each other, and to the
50-kDa hexokinase isozymes of yeast. Further support for
the ‘‘gene duplication’’ view for the origin of mammalian
hexokinases Types I–III has come from the elucidation of
the atomic resolution structure of the Type I enzyme [65,66].
As predicted, both the N and C terminal halves, connected by
a linker region, are very similar in three-dimensional space.
For this reason, it is predicted also on the basis of homology
arguments that the three-dimensional structure of each half
of Type II hexokinase will be highly similar to the other.
Specifically, as it relates to this minireview, one of the
most interesting findings that has emerged from a study of
the two hexokinase halves (N and C) is that only those
derived from the Type II isoform are both catalytic [67]. In
the well-studied Type I isoform, the N half serves only a
regulatory role while the C-terminal half exhibits both
catalytic and regulatory roles [67–69]. Therefore, highly
malignant cancer cells appear to have chosen wisely to
overexpress the hexokinase isoform with the greatest cata-
lytic potential.
4.3. Gene amplification, expression, and regulation
In highly malignant hepatomas expressing the high
glycolytic phenotype, we know that mitochondrial bound
Type II hexokinase activity is more than 100-fold greater
than that found in liver hepatocytes. We know also from our
studies [70] and that of others [19,20,71] that the Type II
hexokinase mRNA levels are exceptionally high in such
tumors. Identifying the factors involved has been of great
interest to us, and, for this reason, we have initiated studies
to determine to what extent the following events/factors are
involved: (1) sequence differences between the normal and
tumor promoters; (2) promoter activation; (3) gene amplifi-
cation; (4) mRNA stability; and (5) changes in DNA
methylation status.
With regard to the above possibilities, initial studies
rendered unlikely that normal/tumor promoter sequence
differences are involved as isolation and sequencing of the
Type II hexokinase promoter from normal hepatocytes and a
highly glycolytic hepatoma (AS-30D) revealed a difference
of no more than 1% [GenBank U19605, AY082375].
Interestingly, both promoters have well-defined TATA and
CAAT boxes indicating precise positioning of transcription
initiation for the Type II hexokinase mRNA transcript [70],
and both are distinct in sequence from those obtained for
hexokinases Types I, III, and IV [72–74]. Moreover, in
contrast to normal/tumor promoter sequence differences,
Fig. 1. (A) Overview of those molecular events that lead to a marked overexpression of mitochondrial bound Type II hexokinase in many cancer cells and the
resultant metabolic consequences. The marked overexpression of the enzyme involves both gene amplification and promoter activation. Other likely events
involved are demethylation and mRNA stability. (B) Schematic of the tumor Type II hexokinase promoter region and a summary of some of its principal
activators. The 4.3-kilobase pair promoter region shown contains well-defined TATA and CAAT boxes and potential response elements for numerous cellular
factors including p53. The promoter is as strong as the SV 40 promoter and, in studies carried out so far, is activated best by hypoxic conditions plus glucose,
and by cAMP plus glucose. (C) A summary of the different ways in which the overexpression of mitochondrial bound Type II hexokinase may promote cancer.
In addition to providing an enhanced production of glucose-6-phosphate to accelerate biosynthesis for growth and glycolysis to combat hypoxic stress, the
overproduced enzyme also inhibits cell death programs dependent on cytochrome c release from the mitochondria. Thus, the relative levels of Type II
hexokinase in a tumor may provide a diagnostic index of its aggressiveness, or its potential to become aggressive.
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activation of the Type II hexokinase promoter is likely to be
a significant contributor to the overexpression of the Type II
enzyme in tumors (Fig. 1B). Thus, reporter gene assays
involving transfection of a highly malignant hepatoma cell
line revealed that hypoxic conditions, glucose, insulin,
glucagon, cAMP, p53, and the phorbol ester TPA [70,75–
77] have a positive effect on transcription. Of these, the
greatest activation observed to date (f 7-fold) was obtained
under hypoxic condition with glucose present and involved
both the proximal and distal regions of the Type II hex-
okinase promoter [77]. This activation appears to involve
also hypoxia inducible factor 1 (HIF-1) [78,79]. The second
best activation response (5- to 6-fold) was obtained in the
presence of dibutyryl cAMP and glucose [75], and requires
further study to localize its site(s) of action within the
promoter.
In addition to promoter activation, we have shown
also that amplification (5- to 10-fold) of the Type II
hexokinase gene may play a significant role in the
overexpression of Type II hexokinase [80]. Finally,
although we have preliminary evidence that mRNA
stability and methylation/demethylation events are
involved also in the high expression of Type II hexoki-
nase, much more work is needed to assess their relative
contribution.
5. Early and late events in tumor progression in relation
to Type II hexokinase gene expression
In recent years, much attention has been given to the view
that clinically diagnosed cancers in humans result from a
series of apparently sequential genetic changes [81–84]. If
we adhere strictly to this view of tumor progression, then it is
only natural for us to inquire at what stage does the over-
expression of an enzyme as seemingly important as Type II
hexokinase occur. On the one hand, it is easy to rationalize
that it is a late event. Support for this comes from studies
conducted many years ago on the Morris rat hepatoma lines
which showed that only those that had the most chromoso-
mal aberrations (e.g., hepatoma 3924A) and grew the fastest
exhibited a high glycolytic rate and a high hexokinase
activity (reviewed in Ref. [5]). However, studies conducted
somewhat later with a different system tend to lead one to
either the opposite conclusion or certainly a modified con-
clusion. Thus, it has been shown that enhanced rates of
glucose transport, utilization, and enhanced activities of
membrane-bound hexokinase, with an increase in the Type
II/Type I ratio, are early events during cellular transformation
of chicken embryo fibroblasts using a temperature-sensitive
Rous Sarcoma virus mutant (ts-68) [85,86]. The answer to
this apparent paradox is not known, but when it is, it may
provide further insight into the multiple roles of Type II
hexokinase in highly malignant tumors and perhaps require
some modification of currently accepted models to explain
tumor progression.
6. Prospects for therapeutic intervention targeted at
mitochondrial bound Type II hexokinase
Considering the multiple roles that Type II hexokinase
plays in highly malignant tumor cells, it clearly represents
an attractive target for therapeutic intervention. Assuming
that one knows via PET scanning and diagnostic test on
biopsies that a given tumor is highly glycolytic and exhibits
elevated levels of Type II hexokinase, then what agents can
be administered that will inhibit this enzyme’s activity or
production, and how should such agents be delivered? We
have been asking this question for the past few years. A
strategy has now been developed and is currently being
subjected to experimental test. Our focus has been on liver
cancer for several reasons. First, hepatocellular carcinoma
(hepatoma) is one of the most common fatal cancers in the
world [87,88] and may soon reach epidemic levels due to
increased viral induced hepatitis [89]. Secondly, liver is a
common site for metastasis of other cancers, for example,
colon cancer [90], and the resultant metastatic tumors that
develop in the liver are frequently the cause of death. Third,
there are numerous model systems, both animal and culture,
for studying liver cancer.
Specifically, we are using two Type II hexokinase-
related approaches to inhibit tumor cells. In the first, we
screen for agents that inhibit both tumor glycolysis and
mitochondrial oxidative phosphorylation. The identified
compounds are then injected intraarterially [91] directly
into a model tumor growing within the liver of a live
animal. The logic of the approach is to completely and
selectively inhibit total cell ATP synthesis fueling the
tumor without harming surrounding normal tissue. One
such agent, 3-bromopyruvate, a potent inhibitor of mito-
chondrial bound hexokinase that inhibits both glycolysis
and mitochondrial oxidative phosphorylation is currently
under study in our laboratory [92]. Significantly, in our
most recent studies, we have shown that a single bolus
injection (intraarterially) of 3-bromopyruvate directly into
liver implanted rabbit tumors kills as many as 90% of the
tumor cells without doing any apparent damage to
surrounding liver tissue, other organs, or the general
health and well being of the animal [93].
We are investigating also approaches that target only Type
II hexokinase, for example, antisense RNA [94], the logic
here being that Type II hexokinase may be so important for
tumor survival that it is unnecessary to simultaneously
inhibit oxidative phosphorylation. If properly packaged,
such targeted antisense agents can also be delivered intra-
arterially. In this regard, it should be noted that many tumors
are fed predominantly by arteries while normal tissues like
liver are fed predominantly from the venous circulation, for
example, the portal vein [95]. Therefore, intraarterial injec-
tion of a drug directly into a tumor is expected to find its
target more quickly while minimizing its entry into the
general circulation. In this way, toxic side effects are mini-
mized or eliminated altogether.
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7. Synopsis
In summary, much evidence has been obtained that
demonstrates that Type II hexokinase is elevated in many
tumors and bound to the outer mitochondrial membrane.
This is not a characteristic of all tumors but is a character-
istic of rapidly growing, poorly differentiated tumors that
are highly malignant. If one believes strictly in the pro-
gression model for tumorigenesis, then one might expect the
high glycolytic/high Type II hexokinase phenotype to be a
property mainly of advanced stage and metastatic tumors.
However, studies conducted in tissue culture show that the
appearance of Type II hexokinase may in some cases also be
an early event. Significantly, not one, but many events
appear to contribute to the overexpression of the Type II
hexokinase protein and the elevation of its total activity in
highly malignant cancer cells (Fig. 1A). These include gene
duplication, amplification, and perhaps demethylation, as
well as promoter activation (Fig. 1B), mRNA stability, and
binding to the mitochondria. The latter membrane binding
event, that may be promoted by signal transduction path-
ways involving the serine/threonine kinase Akt/PKB, sup-
presses the enzyme’s degradation, reduces product
inhibition by G-6-P, and gives the enzyme preferred access
to mitochondrially generated ATP. Mitochondrial binding of
Type II hexokinase also prevents cell death, thus promoting
cancer cell immortality. The net result of all of the above
events is the development of a powerful cancer cell with
specially endowed survival skills (Fig. 1C). It is highly
resistant to abrupt changes in physiological/metabolic states,
to death signals, and to the immune system. Such cells
rapidly multiply and divide frequently forming an encapsu-
lated army of cells (solid tumor), some of which via meta-
stasis seek out new homes in other tissues, and ultimately
via this aggressive behavior assure both the death of the host
and their own death as well. As Type II hexokinase is a
major player in promoting the growth and perhaps the
metastasis of aggressive cancers, this enzyme and its gene
represent ideal targets for therapy.
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